INTRODUCTION
Fatal human prion diseases, including sporadic CreutzfeldtJakob disease (CJD), inherited prion diseases, iatrogenic CJD, kuru and variant CJD, are transmissible spongiform encephalopathies that are characterized by the formation and accumulation of an abnormal isoform of prion protein (PrP) in the brain (Prusiner, 2001) . The PrP res isoform is an insoluble aggregate that is resistant to proteinase K (PK) digestion. The conversion from cellular prion protein (PrP   C   ) into PrP res could be a potential therapeutic target for prion diseases, but the mechanism of the conversion is unclear.
Several animal cell lines, including mouse neuroblastoma cells (Butler et al., 1988; Race et al., 1987) , mouse hypothalamic neuronal cells (Nishida et al., 2000; Schätzl et al., 1997) , mouse Schwann cells (Follet et al., 2002) and rat pheochromocytoma cells (Rubenstein et al., 1984) , have been infected successfully with scrapie agents, and a human neuroblastoma cell line can also be infected with CJD agents (Ladogana et al., 1995) . These cells have been used to study the conversion mechanisms (Lehmann & Harris, 1997) and the subcellular localization (Naslavsky et al., 1997; Vey et al., 1996) of PrP res and to evaluate therapeutic agents (Caughey & Raymond, 1993; Doh-Ura et al., 2000) . However, the efficiencies of infection and propagation of PrP res are relatively low. The mouse cell line SMB was established from a scrapie-infected mouse brain (Clarke & Haig, 1970) and has been used to study the properties of PrP (Birkett et al., 2001) . Recently, stable cell lines were established from mouse peripheral neuroglial cells expressing ovine PrP and simian virus 40 T antigen. These cells were readily infectible by sheep PrP Sc , a scrapie isoform of PrP (Archer et al., 2004) . However, there are currently no human cell lines that have been used to study the conversion mechanism from PrP C into PrP res .
PrP mRNA is expressed not only in neurons, but also in glia (Moser et al., 1995) and PrP Sc accumulates in the cytosol and cell-surface membrane of glial cells (van Keulen et al., 1995) . The role of glial cells in prion disease is not clear. Human glioblastoma T98G cells, like normal cells, become arrested in G 1 phase under stationary-phase conditions (Stein, 1979) . In a previous study, we showed that T98G cells express PrP C mRNA constitutively and produce a high level of endogenous PrP C in G 1 phase . In the present study, we have investigated whether PrP C is converted into PrP res , a marker for prion diseases, in cultured T98G cells under various conditions.
METHODS

Materials.
A primer set for the human PrP coding sequence (CDS) (GenBank accession no. AL133396) [59-CGAGGCAGAGCAGTCA-TT-39, starting 18 nt before the ORF, and 59-AGATGGTGAAAAC-GAGAAGAC-39, ending 6 nt after the ORF (expected product size, 806 bp)] and an internal primer set (59-GGCAGTGACTATGAG-GACCGTTAC-39 and 59-GTAACGGTCCTCATAGTCACTGCC-39, corresponding to nt 424-447 relative to the start site of the ORF) were synthesized chemically. Peptide N-glycosidase F (PNGase F) and BsaAI were purchased from New England Biolabs and RPMI 1640 medium was purchased from Nissui Pharmaceutical. A BCA protein assay kit and SuperSignal West Femto Maximum Sensitivity substrate were from Pierce Biotechnology. Hybond-P PVDF membranes were purchased from Amersham Biosciences. Anti-human PrP mAb 3F4 was purchased from Signet Laboratories and 6H4 from Prionics AG. Fetal calf serum (FCS), horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG, HRP-conjugated goat antirabbit IgG, HRP-conjugated rabbit anti-chicken IgG, aprotinin, leupeptin, PMSF, 4-methylumbelliferyl-b-D-galactoside (4-MUG) and mouse IgG were purchased from Sigma. PK was purchased from Merck and 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride (AEBSF) from Roche Diagnostics. SuperScript II reverse transcriptase and random primers were purchased from Invitrogen. b-Galactosidase-conjugated goat anti-mouse IgG was purchased from American Qualex, DNase I from Takara, KOD-Plus-DNA polymerase from Toyobo and 1,4-diazabicyclo[2.2.2]octane (DABCO) from Nacalai Tesque.
Preparation of antibodies. The preparation of chicken mAb HUC2-13 (IgG) against human PrP peptide residues 25-49 was reported previously (Matsuda et al., 1999) . The preparation of rabbit polyclonal antibody HPC2 (IgG) against human PrP peptide residues 214-230 was also reported previously .
Cell culture. Human glioblastoma cell line T98G (JCRB9041) at nominal passage level 433 was provided by the Japanese Cancer Research Resources Bank (Tokyo, Japan). Human astrocytoma U373MG cells were kindly provided by Dr T. Kasahara (Kyoritsu College of Pharmacy, Tokyo, Japan). Cell cultures stored in liquid nitrogen were thawed as passage 0 (P0) and cultured at 37 uC in monolayers on a T75 plastic tissue-culture flask in RPMI 1640 medium supplemented with 10 % (v/v) heat-inactivated FCS, 60 mg kanamycin ml 21 and 10 mM HEPES/NaOH, pH 7?2. All cell lines were subcultivated routinely at a 1 : 5 or 1 : 10 split ratio once a week.
PCR direct sequencing and RFLP analysis. Extraction of total RNA from the cells and RT-PCR analysis were performed according to a published method with slight modifications. Briefly, 5 mg total RNA was treated with DNase I for 15 min at room temperature. Random primers and SuperScript II reverse transcriptase were added to 20 ml (2?5 mg total RNA) and the mixture was incubated at 42 uC for 60 min to synthesize cDNA. Subsequently, 10 ml cDNA solution was subjected to PCR in a total volume of 50 ml, which included 0?2 mM dNTPs, 1 mM MgSO 4 , 1 U KOD-Plus-DNA polymerase and 50 pmol sense and antisense primers. The amplification programme was as follows: denaturation at 94 uC for 20 s, annealing at 60 uC for 30 s and elongation at 68 uC for 60 s for 40 cycles. Final elongation was performed at 68 uC for 1 min. PCR was carried out in a GeneAmp PCR system 2400 (Applied Biosystems). PCR direct sequencing was performed with a CEQ 2000XL DNA Analysis system (Beckman Coulter) using the primer set for human PrP CDS and an internal primer. Codon 129 polymorphisms were detected by RFLP analysis; the PCR product (200 ng DNA) was digested with 5 U BsaAI for 60 min at 37 uC; after incubation for 20 min at 80 uC, restriction fragments were separated by electrophoresis in 2 % agarose gels and visualized following ethidium bromide staining.
Preparation of whole-cell lysates. All cell lines were plated at 5?0610 5 cells per 9 cm dish (55 cm 2 ) in 10 ml medium on day 0 (D0). The medium was changed every 4 days. At the indicated times, cells were washed twice with ice-cold PBS and scraped into lysis buffer [1?8610 4 cells ml 21 ; 10 mM Tris/HCl (pH 7?5), 150 mM NaCl, 1 % sodium deoxycholate, 0?1 % SDS, 1 % NP-40, 10 mM NaF, 1 mM EDTA, 0?5 mM Na 3 VO 3 , 10 mM tetrasodium pyrophosphate] with protease inhibitor cocktail [0?06 trypsin inhibitor units (TIU) aprotinin ml 21 , 20 mM leupeptin and 1 mM PMSF]. After sonication, insoluble material was pelleted by centrifugation at 500 g for 15 min at 4 uC to yield whole-cell lysates. Protein concentration was determined by the BCA protein assay. Subcellular fractionation. At the indicated times, cells were washed twice with ice-cold PBS and scraped into PBS/2?5 mM EDTA with the protease inhibitor cocktail. After sonication, insoluble material was pelleted by centrifugation at 500 g for 15 min at 4 uC to yield homogenates. The postnuclear fraction was centrifuged at 100 000 g for 60 min at 4 uC to obtain a cytosolic fraction and a membrane fraction. The membrane fraction was dissolved in PBS/ 2?5 mM EDTA with the protease inhibitor cocktail. Protein concentration was determined by the BCA protein assay.
Detergent solubility test. A detergent solubility test was carried out according to a described method (Capellari et al., 2000) with slight modifications. Cells were washed twice with ice-cold PBS and scraped into PBS/2?5 mM EDTA with the protease inhibitor cocktail. After sonication, insoluble material was pelleted by centrifugation at 500 g for 15 min at 4 uC to yield homogenates. The postnuclear fraction was dissolved in 9 vols 0?5 % NP-40/0?5 % deoxycholate/PBS with the protease inhibitor cocktail and centrifuged at 100 000 g for 60 min at 4 uC to obtain a detergent-insoluble pellet fraction and a soluble supernatant fraction. The supernatant fraction was precipitated with 4 vols methanol for 16 h at 220 uC. Both fractions were resuspended in the same volume of lysis buffer.
Protease-resistant PrP assay. To generate material for the protease-resistant PrP assay, aliquots of the sample (50 mg protein) were precipitated with 4 vols methanol for 16 h at 220 uC to remove the protease inhibitor cocktail (Capellari et al., 2000) , centrifuged at 14 000 g for 15 min at 4 uC and the pellet was dissolved in 50 mM Tris/HCl (pH 7?2). Samples were treated with PK (at 10 mg ml 21 unless stated otherwise) at 37 uC for 30 min, according to a described method (Caughey et al., 1999) . After incubation, digestion was stopped by the addition of AEBSF to 4 mM. Samples were prepared with the protease inhibitor cocktail at a concentration that did not inhibit the activity of PK (Fig. 1a , lane 1).
Enzymic deglycosylation. For the removal of Asn-linked oligosaccharides, aliquots of whole-cell lysates were treated with PNGase F as follows : lysates (50 mg protein) were denatured by boiling for 10 min in 0?5 % SDS, 1 % 2-mercaptoethanol. After addition of NP-40 to 1 %, the lysates were incubated at 37 uC for 2 h with 0?77 IUB mU PNGase F in 50 mM phosphate buffer (pH 7?5).
Immunoblotting. Usually, 50 mg total protein (prepared from approximately 1?7610 5 cells) was subjected to SDS gel electrophoresis. Briefly, aliquots of the samples were mixed with 26 electrophoresis sample buffer. After boiling for 10 min, the samples were electrophoresed on 12?5 % acrylamide gel and the proteins were transferred onto PVDF membranes. The membranes were blocked with 0?5 % casein in PBS (casein/PBS) and incubated with anti-prion antibodies in casein/PBS. Immunoreactive bands were visualized with HRP-conjugated anti-IgG and SuperSignal West Femto Maximum Sensitivity substrate, according to the manufacturer's instructions (Pierce Biotechnology).
Indirect immunofluorescence staining. T98G cell monolayers grown on a 15 mm glass coverslip (Matsunami) in a 9 cm dish (55 cm 2 ) were maintained in 10 ml medium. At the indicated times, cells were washed twice with ice-cold PBS and then fixed with 3?7 % formaldehyde in PBS for 30 min at 4 uC. The fixed cells were washed twice with PBS and then treated with 0?2 % Triton X-100 in PBS for 15 min at room temperature. The cells were blocked with 10 % normal goat serum in PBS (NGS/PBS) for 60 min and incubated with antibody (100 ng ml 21 ) for 16 h at 4 uC. After extensive washing with 0?05 % Tween 20/PBS, cells were treated with Alexa 594 goat anti-mouse IgG (H+L) conjugate (5 mg ml 21 ) (Molecular Probes) in NGS/PBS for 1 h at 4 uC, washed with 0?05 % Tween 20/PBS and mounted with 2?5 % DABCO/90 % glycerin/PBS. The stained cells were observed and photographed with the aid of a fluorescence microscope (Olympus).
Competitive ELISA. ELISA was carried out according to a method described previously (Kikuchi et al., 1991) . For a dilution buffer, casein/PBS was used throughout the present study. Briefly, the wells were coated with 100 ng recombinant bovine PrP (rBoPrP) (Takekida et al., 2002) in PBS and left at 4 uC overnight. Appropriately diluted standard rBoPrP solutions or samples were added to the antigencoated wells and incubated at room temperature for 60 min, in a total volume of 50 ml, with 6H4 antibody (460 pg). The wells were washed, incubated with b-galactosidase-conjugated goat anti-mouse IgG for 60 min, washed again and then incubated with 4-MUG as a substrate at 37 uC for 60 min. Enzyme activity was determined by fluorescence intensity measurements.
RESULTS
Production of protease-resistant isoform of PrP in T98G cells
We analysed whole-cell lysates of long-term cultured T98G cells by immunoblotting with anti-PrP antibodies. When we cultured the cells for 38 days after 3 passages [passage 3, day 38 (P3D38)], the lysates revealed two bands (35 and 31 kDa) that reacted with mouse anti-human PrP mAb 6H4 (Fig. 1a , lane 2) and were destroyed completely after digestion with PK (Fig. 1a, lane 1) . When lysates from cells that were cultured for 39 days after 13 passages [passage 13, day 39 (P13D39)] were digested with PK (10, 20 or 30 mg ml 21 ), the 35 kDa band, but not the 31 kDa band, was diminished (Fig. 1b) , indicating the presence of PrP res . We then attempted to detect PrP res formation in longterm cultures of another human glial cell line, U373MG, an astrocytoma line that expresses consistently high levels of PrP C mRNA (Satoh et al., 1998) . The lysates from P11D38 U373MG cells exhibited the 31 kDa band that reacted with the 6H4 antibody and disappeared after digestion with PK (Fig. 1c) . Lysates from P3D150 T98G cells showed a faint 31 kDa band after PK treatment (Fig. 1d) . In contrast, P13D39 T98G cells had produced highly PK-resistant PrP. These data indicated that PrP res propagation in T98G cells required not only long-term culture, but also a high passage number.
Examination of phenotypic variants of PrP res
We first asked whether an inherited or a sporadic CJD-like form of PrP res was propagated in T98G cells. Inherited prion diseases are determined by mutations in the 762 bp CDS of the prion protein gene (PRNP) (Kovács et al., 2002) . We performed PCR direct sequencing of the PRNP mRNA that was expressed in short-and long-term cultured T98G cells and found no mutations other than the presence of both adenine and guanine at the first position of codon 129 (the basis of the common M129V polymorphism) (data not shown). When digested by BsaAI, the 806 bp PCR product from the M129V haplotype (Fig. 2a,  lane 1) yielded products of 402 and 404 bp and also undigested wild-type product (Fig. 2a, lane 2) , which we confirmed by RFLP analysis. These results indicated that T98G cells were heterozygotes, having both methionine and valine at codon 129 of PRNP with no coding-region mutation.
Next, to estimate the size of the deglycosylated PrP res , we treated the lysates from P40D40 T98G cells with PK and/or PNGase F. PNGase F yields a full-length (25 kDa) and an N-terminally truncated (18 kDa) form of PrP C . As shown in Fig. 2b , PNGase F treatment reduced the glycosylated 35 and 31 kDa bands (lane 4) to 25 and 18 kDa (lane 3), representing the deglycosylated full-length and N-terminally truncated forms. An additional PNGase F treatment changed fully glycosylated (31 kDa) and partially glycosylated (23 kDa) forms of PrP res , detectable after digestion with PK (lane 2), to an unglycosylated form of 18 kDa (lane 1). These results established that the size of the deglycosylated PK-resistant fragment in T98G cells was approximately 18 kDa.
Confirming heterogeneity of PrP res by immunoblotting with sets of anti-PrP antibodies
To further investigate the heterogeneity of PrP res from long-term cultured T98G cells, we determined the antigenicity of PrP res . By immunoblotting with sets of antibodies to PrP , we detected a full-length PrP (35 kDa) in lysates from P40D40 T98G cells that reacted with the anti-N terminus PrP antibody HUC2-13 (Fig. 3a, lane 2) , as well as with the 6H4 antibody (Fig. 3c,  lane 2) . Following PK treatment of the lysates, the 31 kDa band was still detected by 6H4 antibody (Fig. 3c, lane 1) , but not by HUC2-13 antibody (Fig. 3a, lane 1) , indicating that PK treatment had cleaved the N terminus of PrP res . The 31 kDa band was also detected by the anti-C terminus PrP antibody HPC2 (Fig. 3d, lane 1) . HPC2 antibody, which reacts strongly with the deglycosylated form of PrP C , but weakly with the glycosylated form , also recognized the N-terminally truncated form of PrP res . Surprisingly, the 3F4 antibody, which recognizes residues 109-112, failed to detect the N-terminally truncated form of PrP res (Fig. 3b) , such as is seen with the HUC2-13 antibody (Fig. 3a) . These experiments showed that the Nterminally truncated form of PrP res in T98G cells lacks the epitope that is recognized by the 3F4 antibody.
Subcellular localization and detergent solubility of PrP res in T98G cells
To determine the subcellular localization of PrP res , we studied the distribution of PrP in P40D40 T98G cells 4) . All lysates were incubated with (lanes 1 and 3) or without (lanes 2 and 4) PNGase F for 120 min. PK-treated lysates were subjected to immunoblot with the 6H4 antibody as described in Methods.
by indirect immunofluorescence staining. Immunoreactive PrP with 6H4 antibody was observed on the cell surface as a bright fluorescent signal (Fig. 4a) , whereas little signal was observed with mouse IgG, a control antibody purified from normal mouse serum (data not shown). We next prepared membrane and cytosolic fractions from homogenates of P40D40 T98G cells and measured the amount of PrP by competitive ELISA using the 6H4 antibody. PrP was recovered predominantly in the membrane fraction (Table 1) ). These data indicated that most PrP res was in the membrane fraction, probably on the plasma membrane. To test the detergent solubility of PrP, the homogenates of P40D40 T98G cells were centrifuged in non-ionic detergents. A large proportion of immunoreactive PrP was found in the supernatant fraction (Fig. 4c, lane 3) , but no PrP was detected in the pellet fraction (Fig. 4c, lane 2) . These were separated into a membrane fraction (mem) and a cytosolic fraction (cyto). Methanol-precipitated lysates were treated with PK (lanes 1, 3 and 5) or left undigested (lanes 2, 4 and 6). PK-treated samples were subjected to immunoblotting with the 6H4 antibody as described in Methods. (c) T98G cells for 40 days after 40 passages (P40D40) were scraped into PBS/ 2?5 mM EDTA and sonicated. Homogenates (H) of 50 mg protein were centrifuged as described in Methods to obtain a nonionic detergent-insoluble pellet (P) and a soluble supernatant fraction (S). Homogenates, pellet and supernatant fractions (50 mg protein each) were subjected to immunoblot with the 6H4 antibody as described in Methods.
experiments indicated that PrP res in T98G cells was nonionic detergent-soluble.
DISCUSSION
The mechanism of the conversion of PrP has not been studied in human cell cultures, due to the lack of a model system. In the present study, we developed such a system by culturing human glioblastoma T98G cells, which express endogenous PrP C constitutively. After reaching a high passage number, long-term cultured T98G cells converted PrP C into PrP res .
Direct sequencing of amplified PRNP mRNA and RFLP analysis indicated that the T98G cells were heterozygotes at codon 129 (129M/V) and that no new coding mutations were present in cells that had been subjected to long-term cultures. The deglycosylated form of PK-treated PrP res in T98G cells migrated at approximately 18 kDa. In human prion diseases, two major types of PrP res can be identified, based on electrophoretic migration; the relative molecular mass of the unglycosylated form is approximately 21 kDa (described as type 1) or 19 kDa (described as type 2) (Parchi et al., 1997) . Accordingly, PrP res in T98G cells is similar to the previously described MV2 phenotypic variant (Parchi et al., 1999a) . However, the size of the deglycosylated PKresistant fragment in T98G cells was smaller than that of the corresponding fragments observed in type 2 PrP res . Most importantly, the 3F4 antibody, which is a wellcharacterized antibody known to target residues 109-112 as its epitope (Kascsak et al., 1987; Matsunaga et al., 2001) , did not react with PK-digested PrP res in T98G cells, suggesting that the N-terminal PrP region up to residue 109 might be absent in PK-treated PrP res in T98G cells. Human PrP res peptide is divided into three regions that are defined by their PK-cleavage patterns: an N-terminal region (residues 23-73) that is invariably PK-sensitive, a C-terminal region (residues 103-231) that is invariably PK-resistant and a variably digested region (residues 74-102), where the major cleavage sites are at G82 in type 1 and at S97 in type 2 . The 3F4 antibody was used to type PrP res . Therefore, there are striking differences in the antigenicity, which reflect the PK-cleavage patterns, between type 2 PrP res in sporadic CJD brain and in T98G cells. It is unlikely, but not impossible, that PK treatment generated conformational changes in the midregion of PrP res that interfered with epitope recognition by the 3F4 antibody. Further studies are needed to classify the type of PrP res in lysates from long-term cultured T98G cells.
So far, human PrP
Sc has been analysed on immunoblots with the 3F4 antibody. Our finding may explain why previous studies have failed to detect PrP res in cultured cells. Interestingly, an N-terminally truncated 18 kDa fragment of PrP (designated C1) in normal and sporadic CJD brains has similar properties except that it is PK-sensitive; it is recognized by the anti-C terminus antibody, but not by the 3F4 antibody, is cleaved around residue 111 and is associated with cell membranes . PrP C from human brain homogenates (n=6) originally displayed a partial PK resistance (20 mg ml 21 for 10 min) and has been detected by the antibody that recognizes residues 145-163, but not by the 3F4 antibody (Buschmann et al., 1998) . Taking the data from the various studies of PrP immunoreactivity into consideration, we believe that it would be better to incorporate an additional antibody that recognizes the C terminus of PrP into the standardly used protease resistance-dependent PrP Sc assay.
Among the sets of antibodies used in this study, the anti-N-terminal portion antibodies (HUC2-13 and 3F4) reacted strongly with the fully glycosylated form and moderately with the partially glycosylated form. In contrast, the antibodies against the C-terminal portion of PrP (6H4 and HPC) reacted moderately with the fully glycosylated form and strongly with the partially glycosylated form. It is possible that PK digestion induces a conformational change of digested PrP and enhances its immunoreactivity to the anti-C-terminal antibodies. Recently, it has been reported that the amino acid motif Tyr-Tyr-Arg (YYR), located in a b-sheet, is exposed in PrP Sc , whilst it is cryptic in PrP C , and that antibodies recognize YYR in PrP Sc , but not in PrP C (Paramithiotis et al., 2003) . Another paper has reported that PK digestion enhances immunoreactivity to the antiPrP antibody that recognizes the epitope YYR, located in a b-sheet (Brun et al., 2004) . These reports suggest that conformation of the C-terminal portion of PrP Sc is essential for immunoreactivity of anti-YYR antibodies. The 6H4 antibody also recognizes residues 144-152 of PrP, including a YYR motif that is located in an a-helix, not in a b-sheet (Korth et al., 1997) . Further study is needed to clarify the immunoreactivity of anti-C-terminal PrP antibodies.
It has been proposed that PrP C is converted into PrP res either on the cell surface or in endocytic cellular compartments. PrP C is a surface protein that contains a glycosylphosphatidylinositol anchor (Stahl et al., 1987) . A portion of PrP Sc is also localized on the cell surface of scrapieinfected mouse neuroblastoma ScN2a cells (Naslavsky et al., 1997; Vey et al., 1996) , although it is also found in lysosomes (Taraboulos et al., 1990) . Subcellular localization of PrP res in long-term cultured T98G cells was similar to that of PrP Sc -infected cells, being present on the cell surface. (Caughey et al., 1991) . Mutant PrP in stably transfected Chinese hamster ovary cells, which express murine homologues associated with human inherited prion diseases, is also non-ionic detergent-insoluble (Lehmann & Harris, 1996) . However, the PrP res in T98G cells is detergent-soluble. PrP res in the human neuroblastoma cell line M-17 BE(2)C carrying the familial subtype CJD, the glutamic acid to lysine substitution at codon 200 (E200K), is also partially non-ionic detergent-insoluble (Capellari et al., 2000) . The present study indicates that not all PrP res is non-ionic detergent-insoluble.
Many cultured cells that express PrP res mutants carrying substitutions of inherited prion disease show considerably less protease resistance (up to 3?3 mg ml 21 for 10 min), compared with PrP res mutants isolated from the human brain (Capellari et al., 2000; Harris, 2001) . In contrast, the PrP res in T98G cells displayed a high resistance to digestion with PK (10 mg ml 21 for 30 min), but was less resistant than PrP res in brain homogenates of sporadic CJD (up to 100 mg ml 21 for 24 h). Sporadic CJD is typically characterized by widespread spongiform degeneration with loss of neurons, gliosis and formation of amyloid plaques (Parchi et al., 1999a) . It has recently been reported that six cases of sporadic fatal insomnia, a prion disease mimicking fatal familial insomnia, had no coding-region mutation of PRNP with the 129 M/M genotype and an approximately 19 kDa deglycosylated PrP res , the same as that of type 2 (Mastrianni et al., 1999; Parchi et al., 1999b) . Familial progressive subcortical gliosis may also be a prion disease, characterized by astrogliosis at the cortex-white matter junction (Petersen et al., 1995) . All patients from two families with that disease showed no coding-region mutation of PRNP, the 129 M/M genotype and the 18?1-19?3 kDa form of deglycosylated PrP res (Petersen et al., 1995) . T98G cells were grown out of human glioblastoma multiforma tumour tissue of a 61-year-old Caucasian man (Stein, 1979) . We consider it possible that he also had a sporadic form of prion disease.
Conversion from PrP C into PrP res is an important process, because most prion diseases are characterized by presence of PrP res . Some knowledge of the conversion mechanism is based on studies of scrapie-infected cells. Recently, it has been reported that several conditions can induce the formation of PrP res in cultured cells. Proteasome inhibitors cause accumulation of the unglycosylated form of PrP res in treated cells (Lehmann & Harris, 1997; Ma & Lindquist, 1999; Yedidia et al., 2001) . PrP that misfolds during maturation in the endoplasmic reticulum is delivered to the cytosol for degradation by proteasomes (Béranger et al., 2002; Ma & Lindquist, 2001; Yedidia et al., 2001) . It has been hypothesized the conversion into PrP res might occur when the number of PrP molecules exceeds the capacity of the cell to degrade them (Ma & Lindquist, 2002) . Another study showed that manganese-treated mouse astrocytes express the glycosylated form of PrP res (Brown et al., 2000) .
Here, we report for the first time the conversion of PrP C into PrP res in the widely used human glioblastoma cell line T98G; a large number of passages and prolonged incubation under routine cell-culture conditions are required. In vitro-generated PrP res is reportedly not sufficient for the production of infectivity (Caughey et al., 2001; Hill et al., 1999) and further study is needed to clarify the infectivity of PrP res in T98G cells (indeed, caution should be taken with T98G cells in the laboratory). Infectivity assays of PrP res in T98G cells are now in progress in transgenic mice.
In conclusion, T98G cells should be a useful model for studying the mechanisms of PrP C conversion into PrP res .
